Oncology outcomes
miR-122 exosomes from fat stem cells sensitize HCC models to chemo
Open access · cc by · source: Europe PMC
Adipose MSC exosomes loaded with miR-122 delivered the microRNA into HepG2 cells, downregulated CCNG1/ADAM10/IGF1R, and increased chemosensitivity in vitro and in xenografts combined with agents such as sorafenib.
Study at a glance
- Design
- Animal / in-vitro — miR-122–loaded AMSC exosomes in HepG2 cells and HepG2 xenografts with chemotherapy
- N
- In-vitro assays reported with n=3 replicates; xenograft group sizes not a single primary analytic N in stored text
- Population
- HepG2 hepatocellular carcinoma cells and nude-mouse xenografts
- Outcome
- Chemosensitivity and xenograft tumour response with miR-122 exosomes
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
AMSCs packaged plasmid-expressed miR-122 into exosomes (~40-fold higher miR-122 in producer cells). 122-Exo raised miR-122 in HepG2 cells vs control exosomes, reduced CCNG1/ADAM10/IGF1R, and increased chemosensitivity via apoptosis and cell-cycle arrest. In xenografts, benefit depended on combining miR-122 transfer with chemotherapy; exosomes alone did not significantly shrink tumours vs vehicle in the reported comparison.
Methodology
Authors transfected adipose tissue–derived MSCs (AMSCs) to express miR-122, harvested exosomes (122-Exo), treated HepG2 HCC cells, and tested chemosensitivity plus HepG2 xenograft responses with regimens including sorafenib (5 mg/kg).
Limitations
This is a preclinical HepG2/xenograft strategy, not a completed human HCC trial. Exosomes alone without chemo did not show significant tumour-volume benefit vs vehicle in the cited comparison. Delivery, dosing, and safety in patients remain open.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Higher tumour EZH2 mRNA associates with portal-vein invasion after HCC resection.
In 66 surgical HCC tumours, EZH2 mRNA exceeded matched nontumour liver and high expression tracked portal-vein invasion (79% vs 39%) without a significant disease-free survival split — a clinicopathological progression signal, not a proven survival assay in this cohort.
Scope note — different question — preclinical chemosensitisation, not surgical clinicopathology
Limits the claim's scope: a different population, assay, or outcome.
AMSC exosomes can deliver miR-122 and sensitise HCC models to chemotherapy.
miR-122–loaded adipose MSC exosomes raised miR-122 in HepG2 cells, downregulated resistance-linked targets (including CCNG1/ADAM10/IGF1R), and increased chemosensitivity in vitro and in xenograft combinations — a preclinical strategy, not a finished patient protocol.
Evidence for the claim as stated.
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
EZH2 marks invasion risk in resected human tumours; methylation signatures classify tissue epigenetically; miR-122 exosomes test a delivery/chemosensitisation idea in models. Shared HCC context does not make them one biomarker or one therapy.
Related papers in this topic
Same topic cluster — not a recommendation engine.